The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.
Tinzaparin vs Warfarin for Treatment of Acute Venous Thromboembolism in Patients With Active Cancer: A Randomized Clinical Trial
Open accessAbstract
IMPORTANCE: Low-molecular-weight heparin is recommended over warfarin for the treatment of acute venous thromboembolism (VTE) in patients with active cancer largely based on results of a single, large trial. OBJECTIVE: To study the efficacy and safety of tinzaparin vs warfarin for treatment of acute, symptomatic VTE in patients with active cancer. DESIGN, SETTINGS, AND PARTICIPANTS: A randomized, open-label study with blinded central adjudication of study outcomes enrolled patients in 164 centers in Asia, Africa, Europe, and North, Central, and South America between August 2010 and November 2013. Adult patients with active cancer (defined as histologic diagnosis of cancer and receiving anticancer therapy or diagnosed with, or received such therapy, within the previous 6 months) and objectively documented proximal deep vein thrombosis (DVT) or pulmonary embolism, with a life expectancy greater than 6 months and without contraindications for anticoagulation, were followed up for 180 days and for 30 days after the last study medication dose for collection of safety data. INTERVENTIONS: Tinzaparin (175 IU/kg) once daily for 6 months vs conventional therapy with tinzaparin (175 IU/kg) once daily for 5 to 10 days followed by warfarin at a dose adjusted to maintain the international normalized ratio within the therapeutic range (2.0-3.0) for 6 months. MAIN OUTCOMES AND MEASURES: Primary efficacy outcome was a composite of centrally adjudicated recurrent DVT, fatal or nonfatal pulmonary embolism, and incidental VTE. Safety outcomes included major bleeding, clinically relevant nonmajor bleeding, and overall mortality. RESULTS: Nine hundred patients were randomized and included in intention-to-treat efficacy and safety analyses. Recurrent VTE occurred in 31 of 449 patients treated with tinzaparin and 45 of 451 patients treated with warfarin (6-month cumulative incidence, 7.2% for tinzaparin vs 10.5% for warfarin; hazard ratio [HR], 0.65 [95% CI, 0.41-1.03]; P = .07). There were no differences in major bleeding (12 patients for tinzaparin vs 11 patients for warfarin; HR, 0.89 [95% CI, 0.40-1.99]; P = .77) or overall mortality (150 patients for tinzaparin vs 138 patients for warfarin; HR, 1.08 [95% CI, 0.85-1.36]; P = .54). A significant reduction in clinically relevant nonmajor bleeding was observed with tinzaparin (49 of 449 patients for tinzaparin vs 69 of 451 patients for warfarin; HR, 0.58 [95% CI, 0.40-0.84]; P = .004). CONCLUSIONS AND RELEVANCE: Among patients with active cancer and acute symptomatic VTE, the use of full-dose tinzaparin (175 IU/kg) daily compared with warfarin for 6 months did not significantly reduce the composite measure of recurrent VTE and was not associated with reductions in overall mortality or major bleeding, but was associated with a lower rate of clinically relevant nonmajor bleeding. Further studies are needed to assess whether the efficacy outcomes would be different in patients at higher risk of recurrent VTE. TRIAL REGISTRATION: clinicaltrials.gov Identifier: NCT01130025.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The National Comprehensive Cancer Network: Present and future directions
McGivney, W. T. (1998) · Cancer · doi:10.1002/(sici)1097-0142(19980515)82:10+<2057::aid-cncr14>3.0.co;2-a · Cited by 16,766
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Kearon (2012) · doi:10.1378/chest.11-2301 · Cited by 6,119
SCHULMAN, S., ANGERÅS, U., BERGQVIST, D., ERIKSSON, B., LASSEN, M. R., & FISHER, W. (2010) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2009.03678.x · Cited by 3,756
Lee, A. Y. Y., Levine, M. N., Baker, R. I., Bowden, C., Kakkar, A. K., Prins, M., Rickles, F. R., Julian, J. A., Haley, S., Kovacs, M. J., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa025313 · Cited by 2,534
Self-citationA Method to Determine the Optimal Intensity of Oral Anticoagulant Therapy
Rosendaal, F. R., Cannegieter, S. C., van der Meer, F. J. M., & Briët, E. (1993) · Thrombosis and Haemostasis · doi:10.1055/s-0038-1651587 · Cited by 2,065
Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy
KHORANA, A. A., FRANCIS, C. W., CULAKOVA, E., KUDERER, N. M., & LYMAN, G. H. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02374.x · Cited by 1,670
Self-citationPrognosis of Cancers Associated with Venous Thromboembolism
Sørensen, H. T., Mellemkjær, L., Olsen, J. H., & Baron, J. A. (2000) · New England Journal of Medicine · doi:10.1056/nejm200012213432504 · Cited by 1,628
Lyman, G. H., Bohlke, K., Khorana, A. A., Kuderer, N. M., Lee, A. Y., Arcelus, J. I., Balaban, E. P., Clarke, J. M., Flowers, C. R., Francis, C. W., et al. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.59.7351 · Cited by 1,371
Self-citationMeyer, G., Marjanovic, Z., Valcke, J., Lorcerie, B., Gruel, Y., Solal-Celigny, P., Le Maignan, C., Extra, J. M., Cottu, P., & Farge, D. (2002) · Archives of Internal Medicine · doi:10.1001/archinte.162.15.1729 · Cited by 796
Self-citationHutten, B. A., Prins, M. H., Gent, M., Ginsberg, J., Tijssen, J. G. P., & Büller, H. R. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.17.3078 · Cited by 748
Hull, R. D., Pineo, G. F., Brant, R. F., Mah, A. F., Burke, N., Dear, R., Wong, T., Cook, R., Solymoss, S., Poon, M.-C., et al. (2006) · The American Journal of Medicine · doi:10.1016/j.amjmed.2006.02.022 · Cited by 607
Prospective Randomized Open Blinded End-point (PROBE) Study. A novel design for intervention trials
Hansson, L., Hedner, T., & Dahlöf, B. (1992) · Blood Pressure · doi:10.3109/08037059209077502 · Cited by 577
Management of venous thromboembolism (VTE) in cancer patients: ESMO Clinical Practice Guidelines
Mandalà, M., Falanga, A., & Roila, F. (2011) · Annals of Oncology · doi:10.1093/annonc/mdr392 · Cited by 512
Anticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Kahale, L. A., Barba, M., Neumann, I., Labedi, N., Terrenato, I., Sperati, F., Muti, P., & Schünemann, H. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub4 · Cited by 428
Legnani, C., Lee, A., Manotti, C., Hirsh, J., D’Angelo, A., Pengo, V., Moia, M., Coccheri, S., & Palareti, G. (2000) · Thrombosis and Haemostasis · doi:10.1055/s-0037-1614120 · Cited by 221
Self-citationImberti, D., Agnelli, G., Ageno, W., Moia, M., Palareti, G., Pistelli, R., Rossi, R., Verso, M., & for the MASTER Investigators (2008) · Haematologica · doi:10.3324/haematol.11458 · Cited by 132
Self-citationIncidental venous thromboembolism in oncology patients
Khorana, A. A., O'Connell, C. L., Agnelli, G., Liebman, H. A., & Lee, A. Y. Y. (2012) · Journal of Thrombosis and Haemostasis · doi:10.1111/jth.12023 · Cited by 82
Self-citationAnticoagulation for the long-term treatment of venous thromboembolism in patients with cancer
Akl, E. A., Labedi, N., Barba, M., Terrenato, I., Sperati, F., Muti, P. C., & Schünemann, H. J. (2011) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd006650.pub3 · Cited by 80
Lee, A. Y. Y., Bauersachs, R. M., Janas, M. S., Jarner, M. F., Kamphuisen, P. W., Meyer, G., & Khorana, A. A. (2013) · BMC Cancer · doi:10.1186/1471-2407-13-284 · Cited by 78
Self-citationLee, A. Y. Y., Levine, M., & Baker, R. I. (2003) · ACC Current Journal Review · doi:10.1016/j.accreview.2003.08.061 · Cited by 19
Self-citationAggarwal, A., van de Geer, A., Faselis, C. J., Buller, H. R., Nisio, M. D., Rickles, F. R., Kamphuisen, P. W., & Kleinjan, A. (2013) · Thrombosis and Haemostasis · doi:10.1160/th13-05-0414 · Cited by 17
Self-citation
Cited by
Konstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehz405 · Cited by 4,916
Self-citationAntithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Lyon, A. R., López-Fernández, T., Couch, L. S., Asteggiano, R., Aznar, M. C., Bergler-Klein, J., Boriani, G., Cardinale, D., Cordoba, R., Cosyns, B., et al. (2022) · European Heart Journal · doi:10.1093/eurheartj/ehac244 · Cited by 3,076
Edoxaban for the Treatment of Cancer-Associated Venous Thromboembolism
Raskob, G. E., van Es, N., Verhamme, P., Carrier, M., Di Nisio, M., Garcia, D., Grosso, M. A., Kakkar, A. K., Kovacs, M. J., Mercuri, M. F., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1711948 · Cited by 1,633
Self-citationKonstantinides, S. V., Meyer, G., Becattini, C., Bueno, H., Geersing, G.-J., Harjola, V.-P., Huisman, M. V., Humbert, M., Jennings, C. S., Jiménez, D., et al. (2019) · European Respiratory Journal · doi:10.1183/13993003.01647-2019 · Cited by 1,619
Self-citation
Metadata
- Authors
- Lee, A. Y. Y., Kamphuisen, P. W., Meyer, G., Bauersachs, R., Janas, M. S., Jarner, M. F., Khorana, A. A., & for the CATCH Investigators
- Venue
- JAMA
- Publisher
- American Medical Association (AMA)
- Published
- 2015-08-18
- Volume
- 314
- Issue
- 7
- Pages
- 677
- ISSN
- 0002-9955 (ISSN-L)
- 0098-7484
- OpenAlex
- W1634950970
- Cited by
- 614
- References
- 22
- FWCI
- 66.12
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.